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Interleukm-8, a neutrophil chemotacttc agent causes excesstve accumulation of the cells in a number of inflammatory diseases. The activity has 
been shown to be mediated through a specific functional receptor present on the surface of neutrophils. No information is available about the ammo 
acids constitutmg the IL-8 binding domain of the receptor. Treatment of neutrophtls with 5.5’-dtthio-bts(3-mtrobenzotc acid), a thiol-specific 
modifier. at the concentrattons of 0.4 mM and 1 mM reduced IL-8 binding ability and IL-g-induced migration of the cells by 45% and 65%. 
respectively. Dithiothrettol could regenerate the bmding capacity and the ligand could protect the receptor from the effect of the reagent. All the 
evidence suggests that one or more critical thiol residues are located m the IL-8 bmdmg site of the receptor which are mdtspensible for normal 
functions of IL-8. 
IL-8 receptor: Neutrophil chemotaxis: IL-8 bmdmg domain; Thtol restdue 
1. INTRODUCTION 
Polymorphonuclear neutrophils (PMNs) provide a 
first line of defence against bacterial and fungal infec- 
tion and play a vital role in host immunity. In non- 
infectious inflammatory diseases, the PMNs are exces- 
sively accumulated at the involved sites and augment 
pathological symptoms and prevent healing [I]. Inter- 
leukin-8 (IL-g). a monocyte-derived neutrophil chemo- 
tactic agent has been identified in a number of inflam- 
matory diseases including psoriasis, rheumatoid arthri- 
tis and lung diseases. Its involvement in other inflamma- 
tory diseases has also been postulated [224]. As IL-S is 
an important proinflammatory cytokine and it induces 
accumulation of PMNs resulting in augmentation of 
inflammatory responses, its mode of action on PMNs 
needs to be explored in detail. 
A specific receptor for IL-8 has been identified on the 
surface of human PMNs and the role of the receptor in 
IL-g-mediated chemotaxis has been demonstrated [5.6]. 
The amino acid sequence encoded by the cDNA clone 
of IL-8 receptor shows that the receptor belongs to the 
superfamily of G-protein-linked receptors that contain 
seven transmembrane domains [7,8]. Two forms of the 
IL-8 receptor are known. One form has high affinity for 
IL-8 itself and two agonists, namely MGSA (GROcr) 
Correspondence address: A.K. Samanta, Division of Immunobiology, 
lndian Institute of Chemical Biology, Calcutta - 700032. India. 
and NAP-2. The other form of receptor shows low af- 
finity for NAP-2 and MGSA but high affinity for IL-S 
[91. 
Although the importance of the IL-S receptor during 
IL-&induced chemotaxis has been demonstrated, the 
mode of interaction of IL-S with its receptor remains 
obscure. Almost nothing is known about the composi- 
tion and architecture of the ligand-binding domain of 
the receptor. 
5,5’-Dithio-bis(2-nitrobenzoic acid), a mild thiol-spe- 
cific modifier originally introduced by Ellman is a 
widely used reagent for location and quantitative deter- 
mination of free -SH groups in proteins as well as in 
various biological fluids and tissues [lo,1 11. Using the 
reagent in the present study. we have shown that the 
ligand-binding ability as well as other functions of the 
IL-8 receptor can be disrupted by treatment with 5,5’- 
dithio-bis(2-nitrobenzoic acid) which were reversibly re- 
stored by DTT, suggesting the presence of active thiol 
residue(s) in the binding site of IL-8 receptor. 
2. MATERIALS AND METHODS 
Human recombinant IL-8 (2 x 10’ U/mg) was a gift from Prof. K. 
Matsushima, Kanazawa University, Japan and from the Dainippon 
Pharmaceutical Company, Osaka, Japan. Dithiothreitol. 5,5’-dithio- 
b&2-mtrobenzoic acid), mtroblue tetrazohum were from Sigma 
Chemical Co . St. Louis, MO, USA. Ftcoll Paque. Sephadex G-IO. 
Dextran T-500 were obtained from Pharmacia Fine Chemicals, 
Uppsala. Sweden. 
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The PMNs were separated from fresh human peripheral venous 
blood of a normal healthy donor by dextran sedimentation followed 
by the Ficoll-Paque centrifugation method [12]. The preparation con- 
tained 90-95% PMNs of which 98% were viable. 
Human recombinant IL-8 (lOpug) was labeled with “‘1 using Bolton 
Hunter reagent [13]. The specific activity of the labeled material was 
1 x 10’ cpm/pg protem. The biological activity of IL-8 was examined 
m a modified Boyden chemotactic chamber (Neuro probe, Inc., Be- 
thesda, MD), using a polyvinyl pyrrohdone-free polycarbonate filter 
(10 pm thick. 3 pm pore size [6.14]). 
2.1. Enzwne release ussa) 
For this assay 2 x lo6 cells1200~1 PBS (pH 7.7) were incubated with 
DTNB for 30 min at 37°C. Reagent-free PMNs were suspended in 
D-PBS and treated with cytochalasm B (5 pg/ml) for 5 min. The PMNs 
were incubated with 100 &ml IL-8 for 45 min at 37°C. Myeloperox- 
idase activity was measured in 100 ~1 of supernatant using citrate- 
phosphate buffer (0.1 M, pH 5.2, 100 ,uI) containing 0.01% HIOz and 
1 mM tetramethyl benzidine. After stoppmg the reaction with 50 fll 
4(N)H$O,. the absorbance was measured at 492 nm [15.16]. 
2.2. NBT test 
For the test PMNs (1 x 10’ce11s/m1) suspended m PBS (pH 7.7) were 
treated with DTNB and incubated for 30 min at 37°C. After removing 
the excess reagents, the functional activity of PMNs was determined 
by NBT test where the capabihty of the cells to reduce the yellow- 
coloured dye to a deep blue product, formazan, was observed. The 
NBT-positive cells were counted under a phase-contrast microscope 
[17.18]. 
3. RESULTS 
As we wanted to examine the functional role of amino 
acid residues constituting the binding domain of IL-8 
receptor in responding cells, we used intact human 
PMNs for our experiments instead of purified IL-8 re- 
ceptor. The PMNs were treated with DTNB, N-eth- 
ylmaleimide and diamide, excess reagents were removed 
and the binding ability of the cells towards ‘zsI-IL-8 was 
measured and biological responses of the modified cells 
(e.g. receptor-ligand internalization and recycling of the 
receptor, chemotaxis, enzyme release) were evaluated 
and compared with the control. 
3.1. Binding inhibition 
Preincubation of PMNs with cell non-penetrating 
thiol reagent DTNB at 37°C resulted in loss of “51-IL-8 
binding capacity in a dose-dependent manner. Thus, 
addition of 0.4 mM and 1 mM reagent to the incubation 
mixture gave 25% and 62% loss, respectively, of binding 
capacity at pH 7.3. The inhibition was increased to 45% 
and 68%, respectively, at the same concentration of rea- 
gents when the pH of the incubation mixture was raised 
to 7.7 (Fig. 1). In a separate experiment, treatment with 
cell penetrating thiol reagents N-ethylmaleimide (1 mM) 
and diamide (0.4 mM) was shown to cause 60-65% 
inhibition of binding of 1’51-IL-8 to PMNs. This sug- 
gests that the PMNs are affected by both the cell non- 
penetrating and cell penetrating thiol modifying rea- 
gents and that the DTNB reaction is pH dependent 
(Fig. 1). Further experiments with DTNB were carried 
out at pH 7.7. because of higher inhibition at this pH. 
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Fig. 1. Effect of DTNB concentration used on the bindmg of “51-IL-8 
to and IL-8 induced migration of neutrophils. Human neutrophils 
(2 x lo6 cells1200 ,uI suspended separately in PBS (pH 7 3 and 7.7) 
containing 1 mg/ml o-glucose) were incubated for 30 min at 37°C with 
various amounts of DTNB as indicated m the figure. After mcubation 
the excess reagent was removed and the cells were suspended in bmd- 
ing medium (D-PBS containing 10 mglml BSA and 1 mg/ml glucose) 
and incubated for 2 h at 4°C with “‘I-IL-8 (4 ngltube). The labeled 
IL-8 bound to neutrophils was measured. The results shown are the 
mean cpm + S.D. of duplicate measurements. Binding capacity at pH 
7.3 (0); binding at pH 7.7 (0); migration of PMNs at pH 7.7 (0). For 
chemotaxis experiments neutrophils (1 x lo6 cells/ml) were treated 
with same doses of DTNB used for binding experiments and after 
removing excess reagents the cells were suspended in binding medium. 
In the lower chamber of a Boyden chemotactic chamber 26 ~1 of 50 
ng/ml IL-8 was added and in the upper chamber 50 ~1 of reagent- 
treated neutrophils (50,0001well) was applied m each well. As a refer- 
ence control fMLP (1 x 10mb M) was used. The chamber was incubated 
in a 5% CO, incubator containing humidified air. After the incubation 
the membrane was removed, fixed with 70% methanol and stained 
with Giemsa and the migrated cells were counted under a phase con- 
trast microscope. The mean count of cells from different position of 
each spotted area was calculated. The figure represents the percent 
mean + S.D. values of IL-8-induced migration of neutrophils m the 
presence of DTNB m duplicate samples. 
3.2. Regeneration of IL-8 binding capacity 
We attempted to reverse the DTNB-mediated loss of 
IL-8 binding ability of PMNs and we observed that 
DTT could restore the binding capacity of DTNB- 
treated PMNs. The binding capacity of PMNs which 
were reduced to 53%, 40% and 35% by treatment with 
0.4 mM, 0.8 mM and 1.2 mM DTNB were increased to 
87%. 80%, and 76%, respectively, on treatment with 2 
mM DTT. Incubation with DTT alone showed a 5-10% 
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Fig. 2. Regeneration of IL-S binding capacity of DTNB-inactivated 
PMNs by dithiothreitol. Human PMNs (2 x 10’/200 ~1) suspended m 
PBS (pH 7.7) were treated with the indicated doses of DTNB and 
incubated for 30 min at 37°C. After removal of excess reagents the 
cells were suspended in D-PBS (pH 7.2) and 2 mM dithiothreitol was 
added and further Incubated for 15 min at 37°C. By removing excess 
dithiothreitol the binding ability of neutrophils was measured as in 
Fig. 1. The data represents the percentage of radiolabeled IL-8 bound 
to the neutrophils obtained from the mean cpm f S.D of duplicate 
measurements. 
decrease of IL-S binding of the control value (Fig. 2). 
Thus the DTNB mediated modification of -SH groups 
of IL-8 receptors were reversibly regenerated by DTT. 
3.3. L&and protection 
To find out whether the DTNB-modified thiol groups 
belong to the IL-8 binding site of the receptor or are 
derived from other proteins, we carried out a ligand 
protection experiment. As can be seen from the data 
presented in Table I, prior incubation of the cells with 
the ligand ensured significant protection against DTNB 
induced inactivation of PMNs at three concentrations 
of the modifier. 
3.4. Effect of total uptake of IL-8 
Incubation of PMNs with IL-8 at 37°C can be used 
to check the functional aspects of the receptor, which 
include binding of the ligand, internalization, separa- 
tion of receptor from ligands and translocation of the 
receptor to re-express on the cell surface [6]. We exam- 
ined these functions of the receptor in PMNs with and 
without treatment with DTNB. The results, presented 
in Fig. 3, demonstrate that total uptake of IL-8 was 
increased with the dose of IL-8 present in the incubation 
mixture. The uptake was reduced to about 50% in 
DTNB treated PMNs. Under identical conditions N- 
ethylmaleimide showed markedly reduced uptake of the 
ligand (IO-20%). 
3.5. Efjkct on chemotaxis 
Directed migration of PMN is a good index of func- 
tional viability of cells and IL&induced chemotaxis can 
be used for this purpose. In the present study, PMNs 
were treated with DTNB and then the IL-&induced 
chemotactic response of PMNs was examined in a Boy- 
den chamber. As is seen in Fig. 1, DTNB-treated cells 
showed inhibition of migration in a dose-dependent 
manner. The reagent-treated cells at concentrations of 
0.1 mM, 0.4 mM and 1.2 mM. showed 15%, 40% and 
70% inhibition of migration, respectively. Under identi- 
cal conditions, 0.1 mM and 0.4 mM N-ethylmaleimide 
could block PMN migration by 60% and 96%, respec- 
tively. 
3.6. Effect on enzyme release 
Degranulation of the lysosomal enzymes is induced 
by chemoattractant and such enzymes can be quantita- 
tively measured in cytocholasin-B-treated cells. This 
function is also mediated by the receptor and is a good 
indication of chemoattractant-mediated cell activation. 
DTNB-treated PMNs, when stimulated by IL-& re- 
leased myeloperoxidase enzyme in a dose-dependent 
manner. For example, cells treated with 0.4 mM, 0.8 
mM and 1.2 mM DTNB when stimulated with 100 
ng/ml of IL-8 showed 76%, 61% and 56% myeloperoxi- 
Table I 
Protection of PMNs by ligand from the effect of DTNB 
Reagent(s) added to PMNs “51-IL-8 bound to 
PMNs (cpm) 
1. Control, acid wash + “‘I-IL-X 8,839 + 372 
3. IL-8 (0.5 pg) + iz51-IL-8 527 + 120 
3. DTNB (0.4 mM). acid wash + “‘I-IL-8 5,921 f 216 
4. IL-8 (0.5 hug) + DTNB (0.4 mM). 
acid wash + “51-IL-8 8,542 + 332 
5. DTNB (0.8 mM). acid wash + ‘251-IL-8 5,172 k 226 
6. IL-S (0.5 pg) + DTNB (0.8 mM), 
acid wash + “‘I-IL-8 7,622 f 296 
7. DTNB (1.2 mM). acid wash + “‘I-IL-8 3,453 f 236 
8. IL-8 (0.5 pg) + DTNB (1.2 mM). 
acid wash + “‘I-IL-8 6,315 ir 321 
For protection experiment. human PMNs (2 x lo6 cells/200 ~1 PBS. pH 
7.7 contaming 1 mg/ml n-glucose) were incubated with and without 
0.5 pug unlabeled IL-l/tube for 2 h at 4°C. Different concentrations of 
DTNB as indicated in the Table were added and further incubated for 
1 h at 4°C. The cells were washed with D-PBS and except for one pair 
(entry 2) the pellets were treated with cold glycine-HCl (pH 3.0, 50 
mM)/NaCl (0.1 M) mixture for 60 s to remove unlabeled IL-8 bound 
to PMNs. The acid-washed cells were suspended in ‘binding medium’ 
(D-PBS containing 10 mg/ml BSA. 1 mg/ml glucose) and 4 ng (40,000 
cpm) of “‘I-IL-8 was added per tube. The data represent the mean 
counts per minute 2 S.D. of radiolabeled IL-8 bound to PMNs in 
duplicate samples 
264 
FEBS LETTERS July 1993 Volume 32.5, number 3 
IO r 
t 
m- a 
0 t 
2 4 - q DTNB(l OmM) 
LFz 
I - El 
NEM (0.8mM) 
A 
% 2 - 
IO 20 30 40 50 _ 
125l IL-8Added to the lncubotlon mixture (cpm x10’) 
Fig. 3. Effect of DTNB and NEM on the total uptake of IL-8 to PMNs 
at 37°C. For this experiment, freshly prepared human neutrophils 
(2 x lo6 cells/200 ~1) suspended in PBS (pH 7.7) containmg 1 mg/ml 
o-glucose were treated with 1 mM DTNB and 0.8 mM NEM sepa- 
rately and incubated for 30 min at 37°C. After removmg the excess 
reagents. the cells were suspended in D-PBS and cultured for 1 h at 
37°C in the presence of various amounts of “‘I-IL-8 as indicated in 
the figure. The bound activity (total uptake of IL-8) to the neutrophils 
was then measured. The result shows mean cpm ? S.D. of duplicate 
samples of a representative experiment. 
dase activity, respectively. Under identical conditions, 
0.4 mM and 0.8 mM N-ethylmaleimide could release 
50% and 38% enzyme, respectively. 
3.1. Functional tests 
The thiol reagents may be cytotoxic to the cells and 
may interfere with the general metabolic functions of 
the cells. For that reason, viability of the cells was exam- 
ined using the Trypan blue dye exclusion test. The via- 
bility of the DTNB-treated cells was 83% and 72% when 
PMNs were treated with 0.2 mM and 0.8 mM DTNB, 
respectively. PMNs treated with the same strength of 
N-ethylmaleimide showed 85% and 79% viability, re- 
spectively. Reduction of NBT to coloured formazan by 
LPS stimulated PMNs reflect general metabolic activi- 
ties of the cells. The DTNB treated cells were subjected 
to this test and the result demonstrates that compared 
to control, 0.2 and 0.8 mM of the reagents showed 88% 
and 78% NBT positive cells for DTNB suggesting that 
the cells are not severely damaged by the reagents. 
4. DISCUSSION 
Directed migration of cells during chemotaxis is initi- 
ated and sustained by the tight association of the che- 
moattractant to its receptor on the target cell. Chemical 
modification of the amino acids in the binding domain 
of the receptor may alter receptor-ligand interaction as 
well as receptor-mediated functions of the cell. 
Interleukin-8 is secreted from the foci of injury during 
the onset of inflammation. Strong binding of IL-8 to its 
receptor on the PMNs, not only indicates the nature 
and direction of the source of the inflammatory stimu- 
lus but also induces activation of the contractile ele- 
ments of PMNs for migration. In the present study, we 
have presented evidence which strongly indicates the 
participation of functionally critical sulfhydryl group(s) 
of the receptor. Covalent modification of these thiol 
groups severely impairs the binding of the ligand to the 
receptor as well as receptor-mediated functions. 
5,5’-Dithio-bis(2-nitrobenzoic acid), introduced as 
mild thiol-specific reagent which converts free sulfby- 
dry1 groups of proteins to thionitrobenzoate groups 
with concomitant liberation of one equivalent of 5-thio- 
2-nitrobenzoate anion [lO,l 11. In our case treatment of 
PMNs with the reagent presumably reacts with the free 
-SH group(s) of cysteine residues in the IL-8 binding 
domain of the receptor resulting in similar thionitroben- 
zoate protein complex. The modification reduces the 
binding of the receptor to IL-8 as is evident from re- 
duced binding of “‘I-IL-8 to PMNs (Fig. 1). DTNB is 
reported to be more reactive towards thiol groups at 
higher pH. We also obtained higher inhibition at pH 7.7 
compared to pH 7.3 indicating more extensive modifica- 
tion of the SH groups at the higher pH. 
Dithiothreitol added to the DTNB modified PMNS 
displaces the thionitrobenzoate groups restoring the 
free -SH groups of the receptor leading to regeneration 
of binding capacity of the receptors towards IL-8 (Fig. 
2). Prior occupation of receptors by unlabeled IL-8 af- 
forded significant protection of the receptor from the 
effects of DTNB. It suggests that -SH group(s) may be 
located at the binding site of IL-8 and thus escape mod- 
ification. Alternatively, binding of IL-8 to the receptor 
may induce conformational changes in the receptor 
making some of the thiol groups inaccessible to the 
reagent (Table I). 
The reagent, DTNB is known to be a cell non-pene- 
trating thiol modifier and as such it could modify -SH 
groups of the surface receptors. After fresh culture of 
DTNB-pretreated PMNs at 37”C, the intracellular un- 
modified receptors were expressed on the cell surface 
and about 50% of total uptake of IL-8 was observed. In 
contrast N-ethylmaleimide, a cell penetrating thiol mod- 
ifier, could modify both intracellular and extracellular 
receptors. For that reason culture of NEM-treated 
PMNs with IL-8 showed only lo-20% total uptake of 
IL-8 (Fig. 3). This also explains the nature of the dose- 
dependent variation of chemotaxis in DTNB-treated 
cells. As can be seen from Fig. 1, with increasing con- 
centration of DTNB used, the inhibition of chemotaxis 
reached saturation well below 100% and about 30% 
residual chemotaxis was observed even at DTNB con- 
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centrations as high as 1.2 mM. This can be explained 
as being due to re-expression of intracellular and buried 
receptors unaffected by DTNB. In contrast, NEM- 
treated cells showed complete inhibition of chemotaxis 
at higher reagent concentrations. Similar difference in 
the levels of enzyme released in DTNB- and NEM- 
treated cells can be explained by the difference in the 
abilities of the two reagents to modify intracellular re- 
ceptors. 
The cytotoxicity of DTNB towards PMNs was exam- 
ined by-the NBT test which showed that the general 
metabolic activities of the cells remains significantly un- 
altered as evidenced from the examination of functional 
test of DTNB treated PMNs. 
All the evidence discussed above strongly indicate the 
presence of DTNB-modifiable -SH groups at the li- 
gand-binding domain of the IL-8 receptor. The cDNA 
encoding the IL-8 receptor from human PMNs shows 
the amino acid sequence of the receptor as having 10 
cysteine residues. In the proposed model of the IL-8 
receptor, 6 cysteine residues are embedded in the trans- 
membrane regions and 4 cysteine residues are exposed 
in the extracellular region [7]. One or more of the ex- 
tracellular cysteine residues may be susceptible to 
DTNB modification. Knowledge about the number of 
-SH groups involved and the mode of their participation 
in the ligand binding must await a detailed characteriza- 
tion of the receptor protein. 
A large number of membrane receptors, e.g. rhodop- 
sin and visual pigments, the family of muscarine recep- 
tors, adrenergic receptors and others belong to the su- 
perfamily of G-protein-linked receptors and have seven 
transmembrane helices like IL-8 receptor. The apparent 
similarities in structure and function among the mem- 
bers of this class of receptors indicate the possibility of 
a common underlying mechanism for the transduction 
of signal [19]. Rhodopsin has also three cysteine resi- 
dues located in the extracellular domains of the second- 
ary structure model. Two of the extracellular cysteines 
are essential for retinal binding, and by replacing cyste- 
ine with serine it has been shown that out of the 10 
cysteine residues only these two are required for main- 
taining the correct tertiary structure of the protein [20]. 
To understand the mechanism of signal transduction in 
this class of receptors some insight into the structural 
interrelationship of the receptor domain is needed. In 
this respect the evidence presented here for involvement 
of cysteine residues in ligand binding of the IL-8 recep- 
tor may be useful in understanding the nature of the 
ligand-receptor interaction of other receptors of this 
family. 
In summary, our studies provide information for one 
or more critical sulfhydryl groups in the IL-8 binding 
site of the receptor which seems to be indispensable for 
normal functioning of the receptor. As the -SH groups 
are critical for normal function, they may be a potential 
target for modulation of IL-8 activity and also for 
screening and designing of antiinflammatory drugs. 
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